No Facility Inspections? No Shortage Of Bogus Pandemic Claims Found Online By US Agencies
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.
You may also be interested in...
FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.
Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the virus, and breakthrough products such as cancer treatments.
The same day Judiciary Chairman Jerrold Nadler and Energy and Commerce Chairman Frank Pallone submit a letter to the FTC, the agency announced work and travel schedule changes it is making in response to the Covid-19 pandemic.